Pages that link to "Q40401407"
Jump to navigation
Jump to search
The following pages link to Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parametersin vitrobut causes loss of the inhibitory potential in living cells (Q40401407):
Displaying 16 items.
- Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. (Q34606199) (← links)
- Variables and strategies in development of therapeutic post-transcriptional gene silencing agents (Q35110219) (← links)
- Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy (Q36073816) (← links)
- Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice (Q37538048) (← links)
- A spermidine-induced conformational change of long-armed hammerhead ribozymes: ionic requirements for fast cleavage kinetics (Q39721813) (← links)
- Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes (Q40393589) (← links)
- A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes (Q40396136) (← links)
- RNA cleavage by small catalytic RNAs (Q40428287) (← links)
- The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes (Q40523113) (← links)
- Ribozymes. Their functions and strategies for their use. (Q41528487) (← links)
- Anti-HIV ribozymes (Q41528506) (← links)
- Antiviral ribozymes. New jobs for ancient molecules (Q41609445) (← links)
- A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets (Q41641558) (← links)
- Chemical engineering of RNase resistant and catalytically active hammerhead ribozymes. (Q41672853) (← links)
- Hammerhead ribozyme kinetics (Q43206267) (← links)
- Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics (Q92101601) (← links)